Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy

NCT02090959 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT02090959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02090959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Lead sponsor
PTC Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
March 20, 2014
Completion date
June 12, 2018
Enrollment
219 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

genetic diseases, inborn, genetic diseases, x-linked, muscular diseases, muscular disorders, atrophic, muscular dystrophies, muscular dystrophy, duchenne, musculoskeletal diseases, nervous system diseases, neuromuscular diseases